Pharmaceutical Product Monograph: Benzathine Penicillin G (1.2 Million Units)
In the pharmaceutical industry, Benzathine Penicillin G is the ultra-long-acting, insoluble salt of Benzylpenicillin. As a pharmacist and manufacturer, I view this molecule as a “Sustained-Release Repository”—it is technically designed to create a “depot” in the muscle tissue that slowly releases penicillin into the bloodstream over 2 to 4 weeks.
At your WHO-GMP facility in Mumbai, Benzathine Penicillin 1.2 MIU is a critical SKU for Public Health Tenders, specifically for the eradication of Rheumatic Fever and Syphilis.
Therapeutic Profile: Primary Indications
The 1.2 Million Unit (MIU) dose is the global standard for prophylaxis and treatment of specific chronic bacterial infections.
| Indication | Clinical Context | Technical Rationale |
| Rheumatic Fever | Secondary Prophylaxis | Gold Standard. Prevents recurrent Group A Streptococcal infections that cause heart valve damage. |
| Syphilis | Primary/Secondary/Latent | A single 1.2 MIU or 2.4 MIU dose is curative for early syphilis due to the sustained plasma levels. |
| Post-Streptococcal GN | Kidney Protection | Eradicates residual Streptococcus to prevent glomerulonephritis (kidney inflammation). |
| Yaws & Bejel | Tropical Diseases | Used in mass drug administration (MDA) programs to eradicate endemic treponematoses. |
Mechanism: The “Depot” Sustained-Release
Benzathine Penicillin works by significantly extending the half-life of the penicillin molecule:
Low Solubility: The benzathine salt is nearly insoluble in water. When injected deep into the muscle, it forms a physical “depot.”
Slow Dissolution: The drug slowly dissolves into the interstitial fluid at a constant rate.
Bactericidal Action: Once in the blood, it acts like regular Benzylpenicillin by binding to Penicillin-Binding Proteins (PBPs), inhibiting cell wall synthesis and causing osmotic lysis of the bacteria.
The Pharmacist’s “Technical Warning”
Strictly IM Only: As a pharmacist, I must emphasize that this drug must never be given IV. Because it is a thick suspension, accidental intravenous injection can cause Embolia Cutis Medicamentosa (Hoigné’s Syndrome) or permanent neurological damage.
The “Deep Gluteal” Technique: It should be administered using a wide-bore needle (usually 21G) into the upper outer quadrant of the buttock to ensure it reaches the deep muscle.
Sensitivity Testing: Since the drug stays in the body for weeks, an allergic reaction can be prolonged and difficult to manage. A skin sensitivity test is mandatory before the first dose.
Jarisch-Herxheimer Reaction: When treating syphilis, patients may experience fever and chills within hours of the injection as the bacteria die off. This is a technical reaction to bacterial endotoxins, not an allergy.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at your facility in Mumbai:
The “Suspension Stability” USP: On your digital marketplace, highlight your Micronized Powder technology. Ensuring the particles are small enough to prevent needle blockage (clogging) while remaining large enough for sustained release is a high-level manufacturing achievement.
Procurement Strategy: This 1.2 MIU strength is the primary volume driver for UNICEF and WHO tenders in Africa and Southeast Asia.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Benzathine Penicillin G (0.6, 1.2, and 2.4 MIU) to support your registration in international B2B contracts.